Detalhe da pesquisa
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634928
2.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
3.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676282
4.
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Clin Genitourin Cancer
; 22(2): 305-314.e3, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38087702
5.
Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes.
Virchows Arch
; 482(3): 493-505, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600115
6.
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
Expert Opin Biol Ther
; 23(5): 407-418, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37036223
7.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Clin Genitourin Cancer
; 21(5): e309-e319.e1, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062658
8.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Target Oncol
; 18(4): 559-570, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369815
9.
A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents.
Rev Port Cardiol
; 41(12): 1047-1051, 2022 12.
Artigo
em Inglês, Português
| MEDLINE | ID: mdl-36257498
10.
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Cancers (Basel)
; 13(1)2021 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33401585
11.
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Diagnostics (Basel)
; 11(1)2021 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33477676
12.
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule.
Hum Pathol
; 93: 6-15, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31442520
13.
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples.
Virchows Arch
; 475(6): 735-744, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31588959
14.
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Cancers (Basel)
; 12(1)2019 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31905816
15.
Digital versus light microscopy assessment of surgical margin status after radical prostatectomy.
Virchows Arch
; 472(3): 451-460, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453523
16.
Tp53 and its potential therapeutic role as a target in bladder cancer.
Expert Opin Ther Targets
; 21(4): 401-414, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28281901
17.
Emerging Immunotargets in Bladder Cancer.
Curr Drug Targets
; 17(7): 757-70, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26844572